

Targeting with Precision: Dosimetry and Isotope Strategies in Radiotheranostic Advancements

SENN

Experts will share recent developments, challenges and trends in the field of Theranostics

- Novel Therapies for Treatments of Cancer and Inflammatory Diseases
- Opportunities and Challenges in the Design of Diagnostics and Radionuclide Therapy
- Targets for Radiopharmaceuticals beyond Oncology

Exclusive Online Webinar followed by Panel Discussion
February, 6th 2025, 16:00 – 17:30 CET

Program

- 16:00 – 16:05** Introduction of Speakers (Senn Chemicals)
- 16:05 – 16:20** Absorbed Dose – Effect Relationship: The Holy Grail of Dosimetry (*ITM Radiopharma*)
- 16:20 – 16:35** Development of an SSTR2 antagonist for clinical use and how isotope choices are driven by the targeting molecule (*Ariceum Therapeutics*)
- 16:35 – 16:50** The Revolution of Radiopharmaceuticals (*Advanced Innovative Partners*)
- 16:50 – 17:05** Cancer integrins – fitting the specific targets to the gaps in guidelines (*TRIMT GmbH*)
- 17:05 – 17:30** Panel Discussion including Q&A

Speakers

PD Dr. Philipp Ritt

VP and Head of Imaging & Dosimetry, ITM

Dr. Manuel Sturzbecher-Höhne
Head of CMC & Radiopharmaceutical Development, Ariceum Therapeutics

Rose Satz
CEO and Co-Founder of Advanced Innovative Partners

Dr. Jakub Simecek
Co-founder and CEO of TRIMT GmbH



PD Dr Philipp Ritt, VP and Head of Imaging & Dosimetry at ITM. ITM is a leading provider of radionuclides and radiopharmaceuticals. Dr Ritt also serves as a Lecturer in Medical Physics at Friedrich Alexander University (FAU) Erlangen-Nürnberg, Germany. With over 40 peer-reviewed publications and book chapters, Dr Ritt's research contributions are widely recognized. His scientific projects have been presented more than 50 times as abstracts and exhibits at top nuclear medicine conferences, including those organized by the Society of Nuclear Medicine (SNM), the European Association of Nuclear Medicine (EANM), and the German Society of Nuclear Medicine (DGN). Dr Ritt brings extensive expertise in all aspects of diagnostic and therapeutic nuclear medicine trials. His clinical focus on radiopharmaceutical dosimetry, SPECT/CT, and PET/CT imaging, along with non-imaging techniques, complements his active research and supports advancements in nuclear medicine's diagnostic and therapeutic clinical trials.



Manuel Sturzbecher-Höhne, PhD is Head of CMC and Radiopharmaceutical Development since the establishment of Ariceum Therapeutics in end of 2021. Manuel gained his PhD in Chemistry in 2009 at the ETH Zurich, Switzerland, before becoming a post-doctoral fellow and scientist at the Berkeley Laboratory, CA, USA where he established new and led ongoing collaborations in the actinide chemistry field. During that time, he also set up Quality Systems to allow for GLP compliant work with radioactive compounds and drugs. Prior to joining Ariceum, Manuel worked as CMC/Site Manager Berlin at Ipsen from 2016 and was responsible for cGMP and cGRPP compliant manufacturing of radiopharmaceuticals for clinical trials.



Rose Satz, CEO and Co-Founder of Advanced Innovative Partners, leads the development of groundbreaking theranostic radiopharmaceuticals, poised to revolutionize nuclear medicine and cancer treatment. With a wealth of experience, including pivotal roles at industry giants like Johnson & Johnson, she is a driving force in biomedical innovation. From overseeing regulatory affairs and quality management to facilitating drug approvals through consultancy, she exemplifies excellence in the field. Committed to advancing biotechnology, Miss Satz spearheads global research and development efforts, focusing on international expansion to bring life-saving treatments to patients worldwide.



Dr. Jakub Simecek is co-founder and CEO of TRIMT GmbH. He has been building up his expertise in theranostics development (integrins, sst2, PSMA, CXCR4) at different institutes followed with the broad application of innovative radionuclides (Ga-68, Lu-177, Ac-225, Bi-213 and others) across the globe. Multiple APIs he has co-developed have found their way to first-in-human studies as well as to routine application later. Currently, he focuses on clinical and commercial translation of novel "cancer integrin" targeting platform, with visible success in multi-malignancy PET imaging and therapeutic approach. Furthermore, he works on translation of group of novel highly specific SMDCS and optical imaging probes.

Contact: sales@sennchem.com

REGISTER HERE!